Alendronate and ibandronate affect osteoclast formation and size differently from risedronate and zoledronate

被引:1
|
作者
Mabilleau, G. [1 ]
Kwaasi, A. A. A. [1 ]
Tsoumpra, M. K. [1 ]
Sabokbar, A. [1 ]
Dunford, J. E. [1 ]
Ebetino, F. H. [2 ]
Russell, R. G. G. [1 ]
机构
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Warner Chilcott Pharmaceut, Rockaway, NJ USA
关键词
D O I
10.1016/j.bone.2011.03.512
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:S220 / S220
页数:1
相关论文
共 1 条
  • [1] Ibandronate is well tolerated by patients intolerant of weekly alendronate or risedronate: Results from the prior study
    Laster, A.
    Bonnick, S. L.
    Friend, K. E.
    Lewieke, E. M.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S136 - S136